Shilpa Medicare

    SHILPAMED
    Pharma
    ₹915.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹17,902 Cr

    P/E
    53.59
    Day range
    ₹906.10 – ₹942.70
    52-week range
    ₹259.50 – ₹1,095.00
    Volume
    3.95 L
    Open
    ₹919.85
    Prev close
    ₹917.30

    Latest results · Q2 FY27(consolidated)Revenue ₹529 Cr+43.0%Profit ₹79 Cr+79.7%Margin 15.0%YoY vs the same quarter last year

    2 red flags to read up on

    • high

      Under Additional surveillance (ASM)

      The exchange has put this stock under Additional surveillance (ASM), Stage I · 18 Nov 2026

    • medium

      Promoter holding falling

      40.13%, down 4.10 pts since 2025-09-30 · 30 Sept 2026

    From NSE and BSE filings. A flag is a reason to read the filing, not a rating.

    Research profile

    Composite 57 / 100

    Factor percentiles

    Value29
    Quality54
    Momentum96
    Low volatility48

    Derived metrics

    Earn. yield
    1.9%
    Graham no.
    ₹224.92
    vs Graham
    -75.4%
    ROE ÷ P/B
    1.5%
    12-1 mom.
    +145.0%
    Return / vol
    3.31
    Magic Formula
    #536
    Piotroski
    5/6
    FCF yield
    -0.2%
    PEG
    0.67

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Shilpa MedicareSHILPAMED₹17,902 Cr53.596.659.8%11.0%27.0%0.24+43.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 3h ago

    Headlines about Shilpa Medicare from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    57.4
    Price / Book
    6.49
    ROE (FY26)
    9.8%
    ROCE (latest year)
    11%
    Dividend yield
    0.06%

    Moving averages (NSE)

    20-day
    ₹923.55
    Price below
    50-day
    ₹965.58
    Price below
    200-day
    ₹622.3
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +13.6%
    Revenue YoY (Sep 2026)
    +43.0%
    Profit YoY (Sep 2026)
    +79.5%
    Operating margin
    27.0%
    Net margin
    14.9%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr-250 Cr0 Cr250 Cr500 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-5%0%5%10%15%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 3 Oct 2025: earlier bars are per pre-bonus share.

    FY15FY16FY17FY18FY19FY20FY21FY22FY23₹0₹1₹2₹3

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales287292293344319331321370410437466529
    Expenses222222222258239252231262296317330387
    Operating Profit65707086817991108114120136142
    OPM %23%24%24%25%25%24%28%29%28%27%29%27%
    Other Income291052-2162-134598
    Interest262424261214191611141213
    Depreciation272727282929293030313534
    Profit before tax14282937421550646112098104
    Tax %67%12%51%51%24%5%5%32%27%10%-3%24%
    Net Profit5241418321547444510810179
    EPS in Rs₹0.26₹1.41₹0.72₹0.92₹1.62₹0.74₹2.40₹2.25₹2.28₹5.51₹5.16₹4.05

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days123

    +35 days since Mar 2021

    Inventory Days291

    -136 days since Mar 2021

    Days Payable113

    +22 days since Mar 2021

    Cash Conversion Cycle301

    -124 days since Mar 2021

    Working Capital Days51

    -21 days since Mar 2021

    Strengths, risks & growth

    Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]

    Strengths

    • Company is expected to give good quarter

    Risks

    • Stock is trading at 6.66 times its book value
    • The company has delivered a poor sales growth of 11.3% over past five years.
    • Company has a low return on equity of 5.51% over last 3 years.
    • Promoter holding has decreased over last 3 years: -9.88%

    Compounded Sales Growth

    10 Years
    +8%
    5 Years
    +11%
    3 Years
    +14%
    TTM
    +37%

    Compounded Profit Growth

    10 Years
    +8%
    5 Years
    +18%
    3 Years
    +109%
    TTM
    +103%

    Stock Price CAGR

    10 Years
    +13%
    5 Years
    +27%
    3 Years
    +71%
    1 Year
    +150%

    Return on Equity

    10 Years
    +6%
    5 Years
    +4%
    3 Years
    +6%
    Last Year
    +9%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter40.13%40.13%40.13%40.13%0.00 pp
    FII10.97%11.07%11.39%12.11%+0.72 pp
    DII8.34%8.58%8.05%8.26%+0.21 pp
    Public40.56%40.21%40.42%39.49%-0.93 pp

    Filed with NSE for Sept 2026: promoters 40.13%, public 59.87%

    Analysts & fund holdings

    75%
    75% recommend buy
    4 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E53.6 vs 45.1
    Sector P/B6.03
    Beta0.26

    Who holds the shares, quarter by quarter

    Mutual funds 4.20% (-0.01 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters40.1%
    • Foreign institutions12.1%
    • Mutual funds4.2%
    • Insurance2.6%
    • Other domestic institutions1.5%
    • Retail16.9%
    • Others22.6%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Bandhan Small Cap Fund1.15%0.59%+0.16 pp
    ICICI Pru ELSS-Tax Saver Fund0.98%1.31%+0.43 pp
    HDFC Pharma and Healthcare Fund0.60%2.92%+0.68 pp
    Aditya Birla SL Small Cap Fund0.33%1.01%+0.43 pp
    Union Small Cap Fund0.28%1.88%+1.88 pp

    Scorecard

    Performance
    High
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Avg

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.

    Computed

    Risk

    Volatility (1Y)
    42.1%
    Downside volatility
    36.0%
    Worst 5% of days
    3.9%
    Average of that tail
    4.9%
    Max drawdown (1Y)
    36.2%
    Below its peak
    14.8%

    Against the market

    Beta vs Nifty 50
    0.78
    Correlation
    0.25
    Relative strength (3M)
    +9.2%
    ATR (14)
    5.5%

    Return

    Return 1M
    -2.4%
    Return 3M
    +13.1%
    Return 6M
    +92.2%
    Return 1Y
    +139.2%
    vs 200-day average
    +47.1%

    Momentum

    RSI (14)
    45.1
    MACD histogram
    0.53
    Stochastic %K
    27.2
    ADX (14)
    19.5
    +DI / −DI
    17.6 / 21.9
    Money flow index
    50.8

    Participation

    Delivery (20d avg)
    43.5%
    vs its 60-day baseline
    +1.0 pts
    Volume vs 20-day
    -0.9σ
    Close vs day's VWAP
    -0.9%
    52-week position
    80 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    5 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    -₹28 Cr
    FCF yield
    -0.2%
    Cash conversion
    1.41
    Accruals ratio
    -0.027
    Net debt
    ₹621 Cr
    Net debt / equity
    0.23
    EV / sales
    10.08
    PEG
    0.67
    Capex intensity
    24.1%
    Revenue CAGR
    36.7%
    Profit CAGR
    209.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹84.0 L
    0 buys · ₹0
    2 sells · ₹84.0 L
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Alpesh Maheshkumar Dalal
    KMP · Market Sale
    Sell4,000₹42.0 L29 Sept 2026
    Alpesh Maheshkumar Dalal
    KMP · Market Sale
    Sell4,000₹42.0 L29 Sept 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.60 Per Share

      4 Sept 2026
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      3 Oct 2025
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      17 Sept 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      6 Sept 2024
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Sept 2023
      ex-date
    • dividend
      ₹1.10

      Annual General Meeting/Dividend - Rs 1.10 Per Share

      19 Sept 2022
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Sept 2021
      ex-date
    • dividend
      ₹1.10

      Dividend - Rs 1.10 Per Share

      20 Sept 2021
      ex-date
    • dividend
      ₹1.10

      Interim Dividend - Rs 1.10 Per Share

      16 Mar 2020
      ex-date
    • dividend
      ₹1.00

      Annual General Meeting/Dividend - Rs 1 Per Share

      12 Sept 2019
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      6 Sept 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend Re 0.70 Per Share (Purpose Revised)

      1 Mar 2018
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      21 Sept 2017
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend Re 0.60 Per Share

      21 Mar 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      20 Sept 2016
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 0.60/- Per Share (Purpose Revised)

      28 Mar 2016
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 2/- Per Share To Re 1/- Per Share

      6 Nov 2015
      ex-date
    • dividend
      ₹1.10

      Annual General Meeting/ Dividend - Rs 1.10/- Per Share

      16 Sept 2015
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting / Dividend - Re 1/- Per Share

      11 Sept 2014
      ex-date
    • bonus
      Not available — not reported in this filing

      Annual General Meeting / Dividend - Rs 1.30/- Per Share / Bonus 1:2

      16 Jul 2013
      ex-date
    • dividend
      ₹1.30

      Annual General Meeting / Dividend - Rs 1.30/- Per Share / Bonus 1:2

      16 Jul 2013
      ex-date

    Company announcements

    Company Update
    Europe GMP Approval Of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana.

    Europe GMP approval of Shilpa Medicare Limited. Unit 4, Jadcherla, Telangana.

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018

    Insider Trading / SAST
    Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

    The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 26, 2026 for Ramakant Innani & Others

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window

    Company Update
    Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Assignment Of ESG Rating By CRISIL ESG Ratings.

    Assignment of ESG Ratings by CRISIL ESG Ratings

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investors/Analysts meet

    Company Update
    USFDA Inspection Of Shilpa Medicare Limited, Unit VII, Analytical Services Division, Hyderabad.

    USFDA Inspection of Shilpa Medicare Limited at Unit VII, Analytical Services Division, Hyderabad.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of Scrutinizers Report on 39th AGM Resolutions along with Voting Results

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Shilpa Medicare's Novel Complex Injectable OERIS (Ondansetron Extended - Release Injection, 100 mg/mL) receives final approval from Subject Expert Committee (SEC) for grant of marketing ....

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Proceedings of 39th Annual General Meeting.

    Company Update
    Initiation Of NCLT Order On FTF Pharma Private Limited, A Wholly Owned Subsidiary Of Shilpa Medicare Limited.

    Initiation of NCLT Order on FTF Pharma Private Limited, a Wholly Owned Subsidiary of Shilpa Medicare Limited.

    Company Update
    Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent /Depository Participants

    Dispatch of letter to shareholders whose e-mail addresses are not registered with Company/ Registrar & Transfer Agent/ Depository Participants.

    Company Update
    Response On The News Item Captioned 'Shilpa Medicare Recalls Over 27K Vials Of Chemotherapy Drug In US' Published In The Online Edition Of The Economic Times On August 17, 2026 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

    Disclosure under Reg.30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

    Corp Action
    Announcement under Regulation 30 (LODR)-Dividend Updates

    Dividend Update

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    Filed with BSE (scrip 530549); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Adjudication order

      Adjudication Order in respect of Shilpa Medicare Limited

      30 Jun 2022
      Read on SEBI
    • Order

      Consent Order on the application submitted by Shri Avinash P. Bhandari in the matter of Shilpa Medicare Ltd

      15 Dec 2009
      Read on SEBI
    • Order

      Consent Order on the application submitted by Shri Pushparaj M. Bhandari in the matter of Shilpa Medicare Ltd

      15 Dec 2009
      Read on SEBI
    • Order

      Consent Order in respect of Shri Pramod Kasat in the matter of Shilpa Medicare Ltd

      30 Nov 2009
      Read on SEBI

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 5 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Shilpa Medicare: common questions

    Answered from the figures on this page.

    Shilpa Medicare last traded at ₹915.30 (NSE, as of 18 Nov 2026). The last session moved it down 0.22%.

    Shilpa Medicare is valued at about ₹17,902 crore (NSE, as of 18 Nov 2026).

    Shilpa Medicare trades at a price-to-earnings ratio of 53.59 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Shilpa Medicare has traded between ₹259.50 and ₹1,095.00 over the past 52 weeks, to 18 Nov 2026. It is currently 78% of the way up that range.

    Shilpa Medicare (SHILPAMED) is classified under Pharma on this site's screener.